公开(公告)号：US20160074462A1

公开(公告)日：2016-03-17

申请号：US14849836

申请日：2015-09-10

Applicant: AbbVie Inc.

Inventor： Sandeep Dutta ,  Rajeev Menon ,  Akshanth Polepally ,  Tianli Wang

IPC: A61K38/07 ,  A23L1/29 ,  A61K31/427 ,  A61K31/513 ,  A61K38/05

CPC classification number: A61K38/07 ,  A23L33/30 ,  A23V2002/00 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/497 ,  A61K31/513 ,  A61K31/7056 ,  A61K38/05 ,  A61K2300/00

Abstract: This application features methods of treating HCV using Compound 1/r, Compound 2 and/or Compound 3.

Abstract translation: 本申请的特征在于使用化合物1 / r，化合物2和/或化合物3治疗HCV的方法。

公开(公告)号：US20150196615A1

公开(公告)日：2015-07-16

申请号：US14670734

申请日：2015-03-27

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Scott C. Brun ,  Daniel E. Cohen ,  Emily O. Dumas ,  Sandeep Dutta ,  Amit Khatri ,  Cheri E. Klein ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki

IPC: A61K38/07 ,  A61K38/05 ,  G06F17/10 ,  A61K45/06 ,  G06F19/12 ,  A61K31/513 ,  A61K31/427

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/473 ,  A61K31/513 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/06 ,  A61K38/12 ,  A61K45/06 ,  G06F17/10 ,  G16B5/00

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Abstract translation: 本发明的特征在于用于治疗HCV的干扰素和不含利巴韦林的疗法。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，所述疗法包括向具有HCV感染的受试者施用至少两种没有干扰素和利巴韦林的直接作用的抗病毒剂。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3）和细胞色素P450（例如利托那韦）的抑制剂。

公开(公告)号：US20150024999A1

公开(公告)日：2015-01-22

申请号：US14503849

申请日：2014-10-01

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Scott C. Brun ,  Daniel E. Cohen ,  Emily O. Dumas ,  Sandeep Dutta ,  Amit Khatri ,  Cheri E. Klein ,  Rajeev M. Menon ,  Sven Mensing ,  Thomas J. Podsadecki

IPC: A61K38/07 ,  A61K38/06 ,  A61K31/513 ,  A61K31/7056 ,  A61K31/427

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/427 ,  A61K31/439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/06 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

Abstract translation: 本发明的特征在于用于治疗HCV的无干扰素治疗。 优选地，治疗过程持续时间较短，例如不超过12周。 在一个方面，治疗方法包括向具有HCV感染的受试者施用至少两种直接作用的抗病毒剂和利巴韦林。 例如，治疗包括给予受试者有效量的治疗剂1，治疗剂2（或治疗剂3），细胞色素P450抑制剂（例如利托那韦）和利巴韦林。

公开(公告)号：US08809265B2

公开(公告)日：2014-08-19

申请号：US13656012

申请日：2012-10-19

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC: A01N37/18 ,  A61K38/00 ,  A61P1/16 ,  A01N43/04 ,  A61K31/70 ,  A61K31/4709 ,  A61K31/7072 ,  A61K31/4725 ,  A61K31/4025 ,  A61K31/501 ,  A61K45/06 ,  A61K31/5377 ,  A61K31/513 ,  A61K31/4178 ,  A61K31/473 ,  A61K31/4196

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/473 ,  A61K31/501 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/7072 ,  A61K38/05 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Abstract translation: 本发明的特征在于用于治疗HCV的干扰素和不含利巴韦林的疗法。 优选地，治疗超过较短的治疗持续时间，例如不超过12周。 在一个方面，所述疗法包括向具有HCV感染的受试者施用至少两种没有干扰素和利巴韦林的直接作用的抗病毒剂。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2（或治疗剂3）和细胞色素P450（例如利托那韦）的抑制剂。

公开(公告)号：US20130344143A1

公开(公告)日：2013-12-26

申请号：US13729313

申请日：2012-12-28

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Joerg Rosenberg ,  Gerd Woehrle ,  Thomas Y. Kessler ,  Joerg Breitenbach ,  Salih Durak ,  Friedrich W. Richter ,  Wei Liu ,  Sandeep Dutta

IPC: A61K9/28 ,  A61K31/167 ,  A61K31/485

CPC classification number: A61K9/28 ,  A61K9/0053 ,  A61K9/209 ,  A61K31/167 ,  A61K31/192 ,  A61K31/485 ,  A61K2300/00

Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

公开(公告)号：US20240115650A1

公开(公告)日：2024-04-11

申请号：US18534967

申请日：2023-12-11

Applicant: ABBVIE INC.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

CPC classification number: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220288153A1

公开(公告)日：2022-09-15

申请号：US17484287

申请日：2021-09-24

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Barry M. Bernstein ,  Andrew L. Campbell ,  Sandeep Dutta ,  Chih-Wei Lin ,  Wei Liu ,  Rajeev M. Menon ,  Thomas J. Podsadecki ,  Tianli Wang ,  Sven Mensing

IPC: A61K38/06 ,  A61K31/454 ,  A61K31/498 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05

Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20160237491A1

公开(公告)日：2016-08-18

申请号：US14536894

申请日：2014-11-10

Applicant: AbbVie Inc.

Inventor： Daniel E. Cohen ,  Kenneth B. Idler ,  Jeffrey F. Waring ,  Emily O. Dumas ,  Sandeep Dutta

IPC: C12Q1/68 ,  A61K38/05 ,  A61K31/7056 ,  A61K31/427 ,  A61K38/12 ,  A61K31/513

CPC classification number: C12Q1/6883 ,  A61K31/402 ,  A61K31/427 ,  A61K31/497 ,  A61K31/513 ,  A61K31/7056 ,  A61K38/05 ,  A61K38/12 ,  C12Q2600/106 ,  C12Q2600/154

Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.

Abstract translation: 本发明的特征在于治疗包含直接作用的抗病毒剂的HCV的治疗。 优选地，将治疗施用于已经被测试以确定IL28B基因的启动子区域内的CpG岛的甲基化状态的HCV感染的患者。 在一个方面，治疗方法包括向具有HCV感染的受试者施用一种或多种直接作用的抗病毒剂和任选的利巴韦林。 例如，治疗包括向受试者施用有效量的治疗剂1，治疗剂2，治疗剂3，细胞色素P450抑制剂（例如利托那韦）和/或利巴韦林。

公开(公告)号：US20150209403A1

公开(公告)日：2015-07-30

申请号：US14606369

申请日：2015-01-27

Applicant: AbbVie Inc.

Inventor： Walid M. Awni ,  Prajakta Badri ,  Daniel E. Cohen ,  Sandeep Dutta ,  Amit Khatri ,  Rajeev M. Menon ,  Thomas Podsadecki ,  Akshanth Polepally ,  Roger Trinh ,  Tianli Wang ,  Jiuhong Zha

IPC: A61K38/06 ,  A61K38/05 ,  A61K45/06 ,  A61K31/513

CPC classification number: A61K38/06 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/496 ,  A61K31/497 ,  A61K31/513 ,  A61K31/55 ,  A61K38/05 ,  A61K45/06 ,  C07K5/0804 ,  A61K2300/00

Abstract: This application features dose adjustment for drugs co-administered with Compound 1, Compound 2 and/or Compound 3.

Abstract translation: 本申请对与化合物1，化合物2和/或化合物3共同施用的药物具有剂量调整。

公开(公告)号：US08685984B2

公开(公告)日：2014-04-01

申请号：US13935987

申请日：2013-07-05

Applicant: AbbVie Inc.

Inventor： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein ,  Thomas J. Podsadecki

IPC: A61K31/4965 ,  A61K31/505 ,  A61K31/47 ,  A61K31/415 ,  A61K31/40 ,  A61K31/675

CPC classification number: A61K38/07 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/473 ,  A61K31/513 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/06 ,  A61K38/12 ,  A61K45/06 ,  G06F17/10 ,  G06F19/12

Abstract: The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).